POLN.SW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Stats
Today's Volume	27 205.00
Average Volume	23 310.00
Market Cap	0.00
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-0.459
ATR14	CHF0 (0.00%)

Polyphor AG Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Polyphor AG Financials

Annual	2020
Revenue:	CHF14.28M
Gross Profit:	CHF0.00 (0.00 %)
EPS:	CHF-4.05

Q2	2019
Revenue:	CHF2 510.00
Gross Profit:	CHF0.00 (0.00 %)
EPS:	CHF-1.463

Q1	2019
Revenue:	CHF2 510.00
Gross Profit:	CHF0.00 (0.00 %)
EPS:	CHF-1.463

Q1	2019
Revenue:	CHF2 510.00
Gross Profit:	CHF0.00 (0.00 %)
EPS:	CHF-1.463

Financial Reports:

No articles found.

Polyphor AG

Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.